G
Graciela Moya
Researcher at Pontifical Catholic University of Argentina
Publications - 15
Citations - 136
Graciela Moya is an academic researcher from Pontifical Catholic University of Argentina. The author has contributed to research in topics: Population & Health care. The author has an hindex of 6, co-authored 15 publications receiving 104 citations. Previous affiliations of Graciela Moya include Facultad de Ciencias Médicas.
Papers
More filters
Journal ArticleDOI
High frequency and founder effect of the CYP3A4*20 loss-of-function allele in the Spanish population classifies CYP3A4 as a polymorphic enzyme.
María Apellániz-Ruiz,L. Inglada-Pérez,M.E.G. Naranjo,Lara Sanchez,Veronika Mancikova,Maria Currás-Freixes,A A de Cubas,Iñaki Comino-Méndez,S Triki,Ahmed Rebai,Mahmood Rasool,Graciela Moya,Manuela Grazina,Giuseppe Opocher,A Cascón,P Taboada-Echalar,Magnus Ingelman-Sundberg,Angel Carracedo,Mercedes Robledo,Adrián LLerena,Cristina Rodríguez-Antona +20 more
TL;DR: The world distribution and origin of CYP3A4*20 mutation is characterized and it is shown that this allele is compatible with a Spanish founder effect and classifies CYP 3A4 as a polymorphic enzyme.
Journal ArticleDOI
Genomic Ancestry, CYP2D6, CYP2C9, and CYP2C19 Among Latin Americans
Fernanda Rodrigues-Soares,Eva M Peñas-Lledó,Eduardo Tarazona-Santos,Martha Sosa-Macías,Enrique Teran,Marisol López-López,Idania Rodeiro,Graciela Moya,Luis R Calzadilla,Ronald Ramírez-Roa,Manuela Grazina,Francisco E Estévez-Carrizo,Ramiro Barrantes,Adrián LLerena,Pharmacogenomics +14 more
TL;DR: The study of a broad spectrum of Native American populations from different ethno‐linguistic groups show how autochthonous diversity shaped the distribution of pharmaco‐alleles and give insights on the prevalence of clinically relevant phenotypes associated with drugs, such as paroxetine, tamoxifen, warfarin, and clopidogrel.
Journal ArticleDOI
Interethnic Variability in CYP2D6, CYP2C9, and CYP2C19 Genes and Predicted Drug Metabolism Phenotypes Among 6060 Ibero- and Native Americans: RIBEF-CEIBA Consortium Report on Population Pharmacogenomics.
M.E.G. Naranjo,Fernanda Rodrigues-Soares,Eva M Peñas-Lledó,Eduardo Tarazona-Santos,Humberto Fariñas,Idania Rodeiro,Enrique Teran,Manuela Grazina,Graciela Moya,Marisol López-López,Alba P Sarmiento,Luis R Calzadilla,Ronald Ramírez-Roa,Rocio Ortiz-Lopez,Francisco E Estévez-Carrizo,Martha Sosa-Macías,Ramiro Barrantes,Adrián LLerena,Pharmacogenomics Ribef +18 more
TL;DR: Pharmacogenetic variation in Latin Americans is understudied, which sets a barrier for the goal of global precision medicine.
Journal ArticleDOI
Pharmacogenetics and ethnicity: relevance for clinical implementation, clinical trials, pharmacovigilance and drug regulation in Latin America.
Martha Sosa-Macías,Enrique Teran,William F. Waters,Martha Fors,Catalina Altamirano,Helgi Jung-Cook,Carlos Galaviz-Hernández,Marisol López-López,Diadelis Remírez,Graciela Moya,Francisco Hernández,Humberto Fariñas,Ronald Ramírez,Carolina Céspedes-Garro,Eduardo Tarazona-Santos,Adrián LLerena +15 more
TL;DR: The present status of clinical implementation and the future perspectives of pharmacogenetics, pharmacovigilance and clinical trials for drug regulation in Latin America compared with the EMA-Pharmacogenomics Working Party and the US FDA initiatives were analyzed.
Journal ArticleDOI
Challenges and Opportunities for Clinical Pharmacogenetic Research Studies in Resource-limited Settings: Conclusions From the Council for International Organizations of Medical Sciences–Ibero-American Network of Pharmacogenetics and Pharmacogenomics Meeting
Eva M Peñas-Lledó,Enrique Teran,Marta Sosa-Macías,Carlos Galaviz-Hernández,José Pedro Gil,Sujit Nair,Shyam Diwakar,Isabel Hernández,Julio Lara-Riegos,Ronald Ramírez-Roa,Ignacio Verde,Eduardo Tarazona-Santos,Juan Molina-Guarneros,Graciela Moya,Lembit Rägo,Adrián LLerena +15 more
TL;DR: The main result of session 1 was that the pharmacogenetics-related ancestry of the population should be considered when designing clinical studies in RLSs, and the social aspects represent the largest proportion of the challenges and opportunities.